Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
NCT00460460 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75
Last updated 2011-01-25
Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.
Conditions
Interventions
- DRUG
-
AZD4877
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Judith Ochs, MD · AstraZeneca
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-03-31
- Completion
- 2007-08-31
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00004871 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
NCT04358393 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT04243785 ·Status: RECRUITING ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00002532 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
NCT03465540 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839 ·Status: RECRUITING ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
NCT03217838 ·Status: TERMINATED ·Phase: PHASE1
-
Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML
NCT01794169 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
NCT04079296 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)
NCT00530699 ·Status: COMPLETED ·Phase: PHASE1
-
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
NCT01814826 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
NCT00430118 ·Status: COMPLETED ·Phase: PHASE3
-
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
NCT07109219 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
NCT02677922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
NCT02864290 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
NCT04275518 ·Status: RECRUITING ·Phase: PHASE1
-
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
NCT04842604 ·Status: COMPLETED ·Phase: PHASE3
-
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02666950 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT03666000 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia
NCT00866073 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma
NCT00195871 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
NCT04964518 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
NCT01265199 ·Status: TERMINATED ·Phase: PHASE1
-
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
NCT06366789 ·Status: RECRUITING ·Phase: PHASE1
-
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
NCT01556477 ·Status: UNKNOWN ·Phase: PHASE2